• Low-Dose Cadmium Activates STAT3 in Lymphangiogenesis

  2026-09-11

  The reference study identifies a previously underappreciated effect of low-dose cadmium on lymphatic vessel growth after corneal injury. Using mouse and human dermal lymphatic endothelial cell models, the authors link cadmium exposure to STAT3 activation, VEGFR3 induction, and dose-dependent changes in endothelial proliferation and migration.

• Deferasirox and the Lysosomal Iron-Stress Switch

  2026-09-10

  The 2025 TCF25 study reframes lysosomal iron as a context-dependent determinant of survival during glucose starvation. This article translates that mechanism into a rigorous Deferasirox research strategy while separating established chelation biology from testable hypotheses in cancer, ischemia, and nutrient-stress models.

• GSK 2837808A: LDHA Inhibition Workflows

  2026-09-10

  GSK 2837808A is a potent lactate dehydrogenase A inhibitor for separating LDHA-dependent lactate output from broader glycolytic behavior. This article provides practical assay workflows, controls, troubleshooting guidance, and a hypothesis-driven bridge from hepatocellular carcinoma research to the NAT1–ENO1–lactate–PD-L1 axis in colorectal cancer.

• Baicalin Methyl Ester and LPS-Induced Barrier Damage

  2026-09-09

  A 2024 Biomedicine & Pharmacotherapy study shows that baicalin methyl ester protects murine intestinal tissue and MODE-K epithelial cells from LPS-associated barrier injury through the P65/TNF-α/MLCK/ZO-1 axis. The work combines animal, cell-based, protein-expression, docking, and immunoprecipitation evidence, while also defining experimental dose ranges relevant to intestinal inflammation research.

• Paroxetine Mesylate: Assay Design for Repurposing

  2026-09-09

  Paroxetine Mesylate is a Selective serotonin reuptake inhibitor with a broader pharmacology than its psychiatric indication suggests. This article presents an assay-centered framework for interpreting its SERT, CYP2D6, MET, and ERBB3 activities in colorectal cancer research without confusing phenotypic data with clinical proof.

• METTL16–SENP3–LTF Axis in HCC Ferroptosis

  2026-09-08

  Wang et al. identify METTL16 as a ferroptosis repressor that promotes hepatocellular carcinoma through an m6A-dependent METTL16–IGF2BP2–SENP3–LTF pathway. The study connects RNA modification, SUMO-dependent protein stability, and labile iron control, providing a mechanistic framework for sensitizing HCC to ferroptosis.

• EZ Cap™ Firefly Luciferase mRNA Workflow

  2026-09-07

  Build more interpretable reporter experiments with a Cap1-capped, polyadenylated RNA designed for direct luciferase expression. This workflow connects careful RNA handling, delivery optimization, purification-aware thinking, and time-resolved bioluminescence readouts for cell-based and in vivo research.

• Merbromin Inhibits SARS-CoV-2 3CLpro Selectively

  2026-09-07

  This study identified merbromin as a selective inhibitor of the SARS-CoV-2 3CLpro/Mpro protease through screening of approximately 6,000 compounds. Kinetic, binding, and docking analyses indicated mixed-type inhibition and two possible binding sites, providing a mechanistic basis for future inhibitor design while leaving cellular efficacy and safety unresolved.

• SP600125: A JNK–Nrf2 Assay Strategy

  2026-09-05

  SP600125 is a JNK inhibitor suited to dissecting how kinase activity intersects with redox stress and Nrf2 loss. This guide develops a time-resolved assay framework grounded in rotavirus research, with practical guidance for inflammation, apoptosis, and cytokine studies.

• V5 Epitope Tag Peptide: Binding-Aware Workflows

  2026-09-04

  The V5 Epitope Tag Peptide supports rigorous protein detection by linking sequence-level identity with antibody-binding behavior. This article explains how epitope accessibility, assay kinetics, and peptide controls improve Western blotting, immunoprecipitation, and advanced imaging decisions.

• Cyclophosphamide: Reliable Cytotoxicity Assays

  2026-09-04

  Learn how Cyclophosphamide SKU A2343 can address variable cytotoxicity, apoptosis, and proliferation assay results through mechanism-aware design, controlled formulation, and documented quality control. This scenario-based guide covers exposure selection, vehicle compatibility, data interpretation, and practical vendor evaluation.

• PPM-18 Workflow for iNOS and NF-κB Studies

  2026-09-03

  PPM-18 enables pathway-focused studies of iNOS expression, NF-κB activation, and inflammatory mediator release without directly targeting constitutive NOS enzymes. This guide translates its chemistry and mechanism into reproducible macrophage, sepsis research, and bone-inflammation workflows while emphasizing solvent control, orthogonal readouts, and practical troubleshooting.

• Candida krusei Apoptosis in Bovine Mammary Cells

  2026-09-03

  The reference study shows that the yeast and hypha phases of Candida krusei trigger bovine mammary epithelial cell apoptosis through different signaling routes. Its phase-resolved co-culture design connects fungal morphology with mitochondrial or death ligand/receptor mechanisms and provides a framework for testing caspase involvement in fungal mastitis research.

• Fenipentol: From Chuanxiong Chemistry to Translation

  2026-09-02

  Fenipentol, also known as 1-Phenyl-1-pentanol, offers a distinctive translational research opportunity at the intersection of Chuanxiong natural-product chemistry, estrogen receptor α signaling, and gastrointestinal secretion biology. This article examines the evidence, experimental priorities, safety context, and strategic path toward validating Fenipentol as a research tool for hepatobiliary, pancreatic, and cardiovascular investigations.

• Mavorixafor in WHIM Syndrome: Phase 3 Evidence

  2026-09-02

  The reference commentary highlights a placebo-controlled phase 3 evaluation of oral mavorixafor, a selective CXCR4 antagonist, in patients with WHIM syndrome. By increasing the duration of neutrophil and lymphocyte recovery and reducing infections, the study supports mechanism-directed treatment for this rare immunodeficiency while leaving important questions about lifelong safety and disease modification unresolved.

8611 records 2/575 page Previous Next 12345 下5页 Last page